JFW



A REGISTERED LIMITED LIABILITY PARTNERSHIP 600 CONGRESS AVENUE. SUITE 2400 AUSTIN, TEXAS 78701-3271 WWW.FULBRIGHT.COM

MKRAWZSENEKOELEBRIGHT.COM DIRECT DIAL: (512) 536-3020

DEC 0 6 2004

TELEPHONE:

(512) 474-5201

FACSIMILE:

(512) 536-4598

December 2, 2004

CERTIFICATE OF MAILING 37 C.F.R 1.8

I certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

December 2, 2004

Date

Michael R. Krawzsenek

#### MS AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

RE:

U.S. Patent Application No. 10/675,860 entitled "NUCLEASE INHIBITOR

COCKTAIL" - by W. Antoni Kudlicki et al.

Our reference: AMBI:052USC1

Sir:

Enclosed for filing in the above-referenced patent application is an Information Disclosure Statement, Form PTO-1449 and references C26-C28.

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/AMBI:052USC1.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully Submitted,

Michael R. Krawzsenek

Reg. No. 51,898

MRK/kmv Encl.: as noted

25370227.1



In re Application of:

W. Antoni Kudlicki et al.

Serial No.: 10/675,860

Filed: September 30, 2003

For: NUCLEASE INHIBITOR COCKTAIL

Group Art Unit: Unknown

Examiner: Unknown

Atty. Dkt. No.: AMBI:052USC1

#### CERTIFICATE OF MAILING 37 C.F.R 1.8

I certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below

December 2, 2004

Date

Michael R. Krawzsenek

### INFORMATION DISCLOSURE STATEMENT

#### MS AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record.

In accordance with 37 C.F.R §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first

Official Action reflecting an examination on the merits, and hence is believed to be timely filed

in accordance with 37 C.F.R § 1.97(b). No fees are believed to be due in connection with the

filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R.

§§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the

Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit

Account No.: 50-1212/AMBI:052USC1.

This application is a divisional application of Serial No. 09/669,301, filed September 25,

2000, and is relied upon for an earlier filing date under 35 U.S.C. § 120. In accordance with

Rule 37 C.F.R. § 1.98(d) only copies of those documents not previously cited and submitted to

the Patent and Trademark Office in prior application Serial No. 09/669,301 are enclosed for the

convenience of the Examiner.

Applicants respectfully request that the listed documents be made of record in the present

case.

Respectfully submitted,

Michael R. Krawzsenek

Reg. No. 51,898

Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P. 600 Congress Avenue, Suite 2400 Austin, Texas 78701 (512) 474-5201

Date:

December 2, 2004

	DEC a come de
Form PTO-1449 (modified)	2004
List of Patents and Publica	tions ton Applicant's

Atty. Docket No. Serial No. AMBI:052USC1 10/675,860

**Applicant** 

W. Antoni Kudlicki et al.

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date: Group: September 30, 2003 Unknown

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art See Page 1

## **U.S. Patent Documents**

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	6,110,968	8-29-00	Bucala et al.	514	482	11-10-98

## **Foreign Patent Documents**

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
•							

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Allewell and Sama, "The effect of ammonium sulfate on the activity of ribonuclease a," Biochem. Biophys. ACTA, 341:484-488, 1974.
	C2	Blackburn et al., "Ribonuclease inhibitor from human placenta: interaction with derivatives of ribonuclease A," J. Biol. Chem. 252:12488-12493, 1977.
	C3	Blumberg, "Creating a ribonuclease-free environment," Methods Enzymol. 152:20-24, 1987.
-	C4	Cazenave, "Idiotypic-anti-idiotypic regulation of antibody sythesis inrabbits," <i>Proc. Natl. Acad. Sci. USA</i> , 74:5122-5125, 1977.
	C5	Chirgwin, et al., "Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease," <i>Biochemistry</i> 18:5294-5299, 1979.
	C6	Chomczynski and Sacchi, "Single step method of rna isolation by acid guanidinium thiocyanate-phenol-chloroform extraction," <i>Anal. Biochem.</i> 162:156-159, 1987.
	C7	Chomczynski, "Solubolization in formamide protects rna from degradation," <i>Nucleic Acids Res.</i> 20:3791-3792, 1992.
	C8	Coburn and Mackie, "Overxpression, purification, and properties of escherichia coli ribonuclease II," J. Biol. Chem. 271:1048-1053, 1996.
	C9	Gilleland and Hockett Jr., "Stability of rna molecules stored in gitc," <i>Biotechniques</i> 25:944-948, 1998.

25374523.1

**EXAMINER:** 

**DATE CONSIDERED:** 

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

	VOILE?		Page	2 of 3
Form PTO-1449 (modified)	DEC 0 6 2004 ES	Atty. Docket No.	Serial No.	
List of Patents and Publications	Applicant's co	's & Applicant		
INFORMATION DISCLOSURE S	- ALVEN	W. Antoni Kuuncki ei u		
(Use several sheets if necess	ary)	Filing Date: September 30, 2003	Group: Unknown	
U.S. Patent Documents	Foreign P	atent Documents	Other Art	
See Page 1	Se	ee Page 1	See Page 1	

# Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C10	Jocoli and Ronald, "Inhibition of ribonuclease activity by bentonite," Can. J. Biochem. 51:1558-1565, 1973.
	Cll	Jones, "On the efficacy of commonly used ribonuclease inhibitors," <i>Biochem. Biophys. Res. Commun.</i> 69:469-474, 1976.
	C12	Lee et al., "The use of immobilized anti-ribonuclease antibodies in the isolation of polyribosomes," <i>Immunochemistry</i> , 9:210-213, 1972.
	C13	Lin, "Inactivation of pancreatic ribonuclease with hydroxylamine-oxygen-cupric ion," <i>Biochim. et Biophys. Acta</i> 263:680-682, 1972.
	C14	Mendelsohn and Young, "Efficacy of sodium dodecyl sulfate, diethyl pyrocarbonate, proteinase k and heparin using a sensitive ribonuclease assay," <i>Biochim. et Biophys. Acta</i> 519:461-473, 1978.
	C15	Murphy et al., "A potent, cost-effective mase inhibitor," Biotechniques 18:1068-1073, 1995.
	C16	O'Leary, "Reducing the Impact of Endogenous Ribonucleases on Reverse Transcription-PCR Assay Systems," Clinical Chemistry, 45(4):449-450, 1999.
	C17	Pelham and Jackson, "An efficient mRNA dependent translation system for reticulocyte lysates," Eur. J. Biochem. 67:247-256, 1976.
	C18	Russo and Shapiro, "Potent inhibition of mammalian ribonucleases by 3' 5'-pyrophosphate-linked nucleotides," <i>J. Biol. Chem.</i> 274:14,902-14,908, 1999.
	C19	Sambrook, et al., "Molecular cloning, a laboratory manual," pp. 7.16-7.52, 1989.
	C20	Spackman et al., "The Disulfide Bonds of Ribonuclease," J. Biol. Chem. 235:648-659, 1960.
	C21	Spicler and Mackie, "Action of mase ii and polynucleotide phosphorylase against mas containing stem-loops of defined structure," <i>J. Bacteriology</i> 182(9): 2422-2427, 2000.
	C22	Trent et al., "A comparison of new world alphaviruses in the western equine encephalomyelitis complex by immunochemical and oligonucleotide fingerprint techniques," J. Gen. Virol., 47:261-282, 1980.
	C23	Wolf et al., "A mechanism of the irreversible inactivation of bovine pancreatic ribonuclease by diethylpyrocarbonate," Eur. J. Biochem. 13:519-525, 1970.
	C24	Wu, et al., "Methods in Gene Biotechnology," CRC Press, Boca Raton, FL, pp. 29-56, 1997.

25374523.1

**EXAMINER:** 

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

A A	/		ध्र	
Form PTO-1449 (modified)	B OFF.	0 6 2004	8	A
	(E		/نځ	A
List of Patents and Publication	s forest	plicant's		A
	_	C. K. M.		V
INFORMATION DISCLOSU	RE STAT	rement	-	
				H

Atty. Docket No. Serial No. AMBI:052USC1 10/675,860

Applicant

W. Antoni Kudlicki et al.

(Use several sheets if necessary) Filing Date: September 30, 2003 Group: Unknown

U.S. Patent Documents

See Page 1

Foreign Patent Documents
See Page 1

Other Art

See Page 1 See Page 1 See Page 1

# Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C25	Zale and Klibanov, "Why does ribonuclease irreversibly inactivate at high temperatures?," Biochemistry 25:5432-5444, 1986.
	C26 <b>₹</b>	Co-Pending U.S. Patent Application 10/786,875, filed February 25, 2004. (AMBI:089US)
	C27 /	Pending PCT Application No. PCT/US2004/005663 filed February 25, 2004. (AMBI:095WO)
	C28 🖊	Pending U.S. P rovisional Application 60/547,721 filed February 25, 2004. (AMBI:096USP1)

25374523.1

**EXAMINER:** 

**DATE CONSIDERED:** 

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.